Almac Achieves Double Success at Business Award Ceremony
Almac are delighted to announce the exceptional achievement of picking up two category awards at the prestigious Belfast Telegraph Business Award gala ceremony in association with British Airways. The awards are in their 12th year and are the premier symbol in Northern Ireland of commercial, industrial and social enterprise achievements.
The winning “Excellence in Innovation” entry focussed on the development of our Antibody Drug Conjugation (ADC) offering provided by the Science’s biocatalysis group headed up by Professor Tom Moody. Almac has developed the innovative ADC science from the laboratory bench into successful, novel, commercial offerings that are now part of their existing business portfolio.
The trophy was presented by Kevin Traynor, Belfast Telegraph’s Digital Director to Dr William Watters, Isotope Chemistry Manager at Almac’s Sciences Business Unit. The other 2 finalists in this category were Core Systems and Randox Laboratories.
The “Excellence in Technology” award recognised the advances made by the Diagnostics team in relation to the recently announced DNA Damage Repair Deficiency (DDRD) research. This new technology offers significant advances in the treatment of cancer and has recently been the subject of a collaboration with US-based Genomic Health Inc to bring its benefits to patients worldwide.
The trophy was collected by Michael Sloan, VP Business Development for the Diagnostics Business Unit from Karen Blair, MD, Clever Fulton Rankin who sponsored the award. Other finalists in this category were PathXL and Taggled Ltd.
Alan Armstrong, CEO, Almac Group commented on receiving the honours: “We are delighted to receive these prestigious awards and is a tremendous tribute to the pioneering work carried out on a daily basis by our dedicated and talented teams here at Almac. It is especially pleasing to achieve recognition for our work within the context of such strong local competition and is testimony to the true innovation and technology that we pride ourselves on within the pharmaceutical and biotech industry.”
www.almacgroup.com
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance